JP2022504760A5 - - Google Patents

Info

Publication number
JP2022504760A5
JP2022504760A5 JP2021520113A JP2021520113A JP2022504760A5 JP 2022504760 A5 JP2022504760 A5 JP 2022504760A5 JP 2021520113 A JP2021520113 A JP 2021520113A JP 2021520113 A JP2021520113 A JP 2021520113A JP 2022504760 A5 JP2022504760 A5 JP 2022504760A5
Authority
JP
Japan
Application number
JP2021520113A
Other languages
Japanese (ja)
Other versions
JP7513286B2 (ja
JP2022504760A (ja
JPWO2020074010A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/110904 external-priority patent/WO2020074010A1/zh
Publication of JP2022504760A publication Critical patent/JP2022504760A/ja
Publication of JP2022504760A5 publication Critical patent/JP2022504760A5/ja
Publication of JPWO2020074010A5 publication Critical patent/JPWO2020074010A5/ja
Priority to JP2024099957A priority Critical patent/JP2024123152A/ja
Application granted granted Critical
Publication of JP7513286B2 publication Critical patent/JP7513286B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520113A 2018-10-12 2019-10-12 化学療法難治性がんの治療のための新しい併用薬方法 Active JP7513286B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024099957A JP2024123152A (ja) 2018-10-12 2024-06-20 化学療法難治性がんの治療のための新しい併用薬方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811195239.3 2018-10-12
CN201811195239 2018-10-12
PCT/CN2019/110904 WO2020074010A1 (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024099957A Division JP2024123152A (ja) 2018-10-12 2024-06-20 化学療法難治性がんの治療のための新しい併用薬方法

Publications (4)

Publication Number Publication Date
JP2022504760A JP2022504760A (ja) 2022-01-13
JP2022504760A5 true JP2022504760A5 (https=) 2022-10-20
JPWO2020074010A5 JPWO2020074010A5 (https=) 2022-10-20
JP7513286B2 JP7513286B2 (ja) 2024-07-09

Family

ID=70163618

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021520113A Active JP7513286B2 (ja) 2018-10-12 2019-10-12 化学療法難治性がんの治療のための新しい併用薬方法
JP2024099957A Pending JP2024123152A (ja) 2018-10-12 2024-06-20 化学療法難治性がんの治療のための新しい併用薬方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024099957A Pending JP2024123152A (ja) 2018-10-12 2024-06-20 化学療法難治性がんの治療のための新しい併用薬方法

Country Status (15)

Country Link
US (2) US12257227B2 (https=)
EP (1) EP3865130A4 (https=)
JP (2) JP7513286B2 (https=)
CN (2) CN120168498A (https=)
AU (1) AU2019357933B2 (https=)
BR (1) BR112021006898A2 (https=)
CA (1) CA3115869A1 (https=)
EA (1) EA202190771A1 (https=)
IL (1) IL282228A (https=)
MX (1) MX2021004151A (https=)
PH (1) PH12021550815A1 (https=)
SG (1) SG11202103707TA (https=)
TW (1) TWI848990B (https=)
WO (1) WO2020074010A1 (https=)
ZA (1) ZA202102494B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
EP2983790A2 (en) * 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
US20180085341A1 (en) 2015-04-17 2018-03-29 Boston Biomedical, Inc. Methods for treating cancer
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CN107766371B (zh) * 2016-08-19 2023-11-17 中兴通讯股份有限公司 一种文本信息分类方法及其装置
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021018450A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021013128A2 (https=)
BR112021018484A2 (https=)
BR112021017949A2 (https=)